Clearmind Medicine (CMND) Operating Income (2022 - 2023)
Clearmind Medicine (CMND) posted quarterly Operating Income of -$1.2 million for Q2 2023, up 30.2% year-over-year from -$940024.3 in Q2 2022, and up 33.22% quarter-over-quarter from -$1.8 million in Q1 2023.
Clearmind Medicine (CMND) Operating Income (2022 - 2023) Analysis & Trends
Clearmind Medicine's Operating Income history runs 2 years deep, the most recent figure standing at -$1.2 million for Q2 2023.
- In Q2 2023, Operating Income rose 30.2% year-over-year to -$1.2 million; the TTM figure through Apr 2023 stood at -$6.5 million (changed N/A YoY), while the FY2022 annual figure was -$6.6 million, down 126.9% from the prior year.
- Operating Income for Q2 2023 stood at -$1.2 million, up from -$1.8 million in the prior quarter.
- The five-year high for Operating Income was -$1.2 million in Q2 2023, with the low at -$1.8 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Clearmind Medicine | 520,887.91 | -13.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2023 | -1.22 Mn |
| Jan 31, 2023 | -1.83 Mn |
| Apr 30, 2022 | -1.75 Mn |
| Jan 31, 2022 | -1.65 Mn |